Drugs /

cyt-0851

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for cyt-0851

Cyt-0851 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cyt-0851, 1 is phase 1/phase 2 (1 open).

BCL2 Fusion, BCL6 Fusion, and ER Negative are the most frequent biomarker inclusion criteria for cyt-0851 clinical trials.

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, B-cell non-hodgkin lymphoma, and breast carcinoma are the most common diseases being investigated in cyt-0851 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cyt-0851
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cyt-0851 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
RAD51

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.